Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
MannKind Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MNKD
Nasdaq
2834
https://mannkindcorp.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for MannKind Corp
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
- May 13th, 2024 4:00 pm
MannKind First Quarter 2024 Earnings: Beats Expectations
- May 10th, 2024 10:56 am
MannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...
- May 10th, 2024 7:01 am
MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript
- May 9th, 2024 3:47 pm
Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's Why
- May 9th, 2024 10:47 am
MannKind (MNKD) Q1 2024 Earnings Call Transcript
- May 9th, 2024 4:15 am
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
- May 8th, 2024 11:30 pm
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
- May 8th, 2024 11:10 pm
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
- May 8th, 2024 8:18 pm
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- May 6th, 2024 10:05 am
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
- May 1st, 2024 8:00 pm
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
- Apr 30th, 2024 10:05 am
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
- Apr 29th, 2024 10:05 am
MannKind Repays Certain Debt Obligations
- Apr 3rd, 2024 10:00 am
MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
- Apr 1st, 2024 2:30 pm
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
- Mar 29th, 2024 3:30 pm
MannKind Announces CFO Transition
- Mar 26th, 2024 8:05 pm
Jim Cramer Says You Should Avoid These 11 Stocks
- Mar 25th, 2024 3:45 pm
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
- Mar 11th, 2024 10:05 am
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
- Mar 5th, 2024 11:05 am
Scroll